The effect of short-term dutasteride intake in early-stage prostate cancer: Analysis of 148 patients who underwent three-dimensional prostate mapping biopsy

Urology

Volumn 76, Issue 5, 2010, Pages 1067-1071

  Barqawi, Al B ^a   O'Donnell, Colin I ^b   Siomos, Vassilis J ^b   Hou, Amy H ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; BIOPSY, NEEDLE; CHEMOPREVENTION; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TERTIARY PREVENTION; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77957022564     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.02.063     Document Type: Article

References (17)

1. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to PSA screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
2. S.M. Dehm, and D.J. Tindall Molecular regulation of androgen action in prostate cancer J Cell Biochem 99 2006 333 344
3. I.M. Thompson, and P.J. Goodman The influence of finasteride on the development of prostate cancer N Engl J Med 349 3 2003 215 224
4. F.H. Schrder, and C.H. Bangma Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after radical therapy prostate cancer study BJU Int 103 2009 590 596
5. N. Fleshner, L.G. Gomella, and M.S. Cookson Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial Contemp Clin Trials 28 2007 763 769
6. M. Gleave, and J. Qian The effects of the dual 5ARI dutasteride on localized prostate cancerresults from a 4month pre-radical prostatectomy study Prostate 66 2006 1674 1685
7. Y. Fradet, and M. Lodde Phase II study of treatment with 5ARI in low risk CaP Urology 72 Suppl 5A 2008 S43
8. F. Rabbani, and N. Stroumbakis Incidence and clinical significance of false-negative sextant prostate biopsies J Urol 159 1998 1247 1250
9. J. Miller, and C. Perumalla Complications of transrectal vs transperineal prostate biopsy ANZ J Surg 75 2005 48 50
10. G.S. Merrick, and Taubenslag The morbidity of transperineal template-guided prostate mapping biopsy BJU Int 101 2008 1524 1529
11. E.D. Crawford, and S.S. Wilson Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy BJU Int 96 2005 999 1004
12. G. Onik, and W. Barzell Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy Urol Oncol 26 5 2008 506 510
13. F.B. Serkin, and D.W. Soderdahl Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7 Urol Oncol 2009 Corrected Proof, In press
14. D.G. Bostwick Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies Am J Surg Pathol 18 1994 796 803
15. J. Adolfsson Watchful waiting and active surveillance: the current position BJU Int 102 2008 10 14
16. G. Steineck, and F. Helgesen QOL after radical prostatectomy or watchful waiting N Engl J Med 347 2002 790 796
17. D.M. Latini, and S.L. Hart The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance J Urol 178 2007 826 832